Difflam Anti-Inflammatory Lozenges

Quick links to important sections

Difflam Anti-Inflammatory Lozenges

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Difflam Anti-Inflammatory Lozenges

Property Description
Active Ingredients Benzydamine Hcl, Cetylpyridinium Chloride
Form Lozenge (Solid Oral Dosage Form)
Pharmacological Class Topical NSAID and Antiseptic Agent
Common Use Symptomatic relief of oropharyngeal inflammation
Origin Synthetic Chemical Entities

Difflam Anti-Inflammatory Lozenges is an over-the-counter (OTC) medicine presented as a fixed-dose combination product for oromucosal administration. This dual-action preparation combines two synthetic chemical entities that offer combined therapeutic effects intended for localized symptomatic relief within the mouth and throat. The lozenge is a recognized choice for managing the acute symptoms of a common sore throat or mouth irritation.


What is the Composition and Type of Difflam Anti-Inflammatory Lozenges?

The lozenge relies on two primary active ingredients: Benzydamine Hcl (Benzydamine Hydrochloride) and Cetylpyridinium Chloride. Benzydamine is structurally classified as an indazole NSAID (Non-steroidal Anti-inflammatory Drug), unique for its primary function as a potent topical anti-inflammatory agent and a local analgesic. The compound possesses pain-relieving properties utilized in localized treatment.

The secondary component, Cetylpyridinium Chloride, is a quaternary ammonium compound recognized for its general antiseptic properties and specific use in addressing minor infections of the mouth and throat. This dual pairing establishes the lozenge as a distinct preparation, differentiating it from simple anesthetics by integrating both anti-inflammatory management and surface microbial control. The lozenge format ensures the slow release of these agents, maximizing contact time with irritated tissues.


Why is a Dual-Action Formula Used for the Throat?

The primary purpose of combining the two compounds is to provide comprehensive symptomatic relief for acute oropharyngeal discomfort. The Benzydamine component achieves inflammation inhibition and a local numbing effect, directly targeting the source of swelling and pain. Concurrently, the Cetylpyridinium component provides essential antimicrobial activity on the mucosal surface, helping to manage the local microbial load often accompanying irritation. This dual functionality is an effective strategy, ensuring the preparation addresses the two most common components of acute, localized oropharyngeal inflammation simultaneously.

What side effects are possible with Difflam Anti-Inflammatory Lozenges?

The official safety profile for the fixed-dose lozenge is defined by its localized action and structured regulatory classifications, covering both minor local effects and rare systemic adverse reactions.

Documented Adverse Reactions and Frequency

Adverse reactions are officially grouped by System-Organ Class. Gastrointestinal disorders, specifically within the oral cavity, involve the most reported effects. These include localized sensory changes such as oral numbness, a stinging feeling, and burning of the oral mucosa. These sensations may be classified in regulatory documents as very rare or having a not known frequency, and some reports indicate the stinging sensation may resolve with continued treatment.

Serious reactions are listed in the official safety profile, mostly related to the Immune system disorders and Respiratory, thoracic and mediastinal disorders classes. Rare reactions include hypersensitivity reactions, urticaria, bronchospasm, and laryngospasm. More severe allergic events, such as anaphylactic shock and angioedema (swelling of the face, lips, or tongue), are also documented with a not known frequency.

Other notable documented effects include photosensitivity, classified as uncommon.

Safety Constraints and Considerations

Regulatory documents establish several constraints on the use of the product. The formulation is not recommended during pregnancy or breast-feeding due to limited safety data and the pharmacological class of benzydamine. Caution is advised for patients with bronchial asthma due to the potential risk of precipitating bronchospasm. Furthermore, uninterrupted treatment is generally not recommended to exceed seven days and the product should not be used concurrently with other antiseptics.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents specify that an overdose of these lozenges is associated with the accidental ingestion of an excessive dose, which can lead to systemic effects requiring immediate medical attention. The potentially lethal dose of the Cetylpyridinium Chloride component is cited in toxicological findings as approximately 1 to 3 grams.

Documented Overdose Manifestations

The clinical presentation of an overdose is primarily characterized by effects on the Central Nervous System (CNS), respiratory, and cardiovascular systems.

System Affected Documented Signs and Symptoms
CNS excitement, convulsions, ataxia, shivering or tremor, vomiting, and CNS depression.
Respiratory/CV dyspnoea (difficulty breathing), cyanosis, and hypotension (low blood pressure).

Severe Outcomes and Emergency Action

Overdose manifestations may escalate to severe, life-threatening outcomes, including coma and asphyxia due to respiratory muscle paralysis. The official labeling confirms that no specific antidote is known for this overdose, and treatment for acute overdose is described as purely symptomatic.

Regulatory Mandate for Urgent Medical Care

The regulatory instruction for handling an overdose is mandatory: In the event of accidental ingestion of an excessive dose, patients must immediately tell a doctor or go to the nearest hospital. This requirement ensures prompt symptomatic and supportive care is administered under continuous medical observation due to the potential for severe systemic complications.

Therapeutic Uses of Difflam Anti-Inflammatory Lozenges

What Difflam Anti-Inflammatory Lozenges Treats: Main Uses and Benefits


Managing Localized Acute Pain and Oropharyngeal Inflammation

This lozenge is commonly used to help with symptomatic relief for acute sore throat (pharyngitis) and the discomfort associated with tonsillitis. It is applied in clinical settings marked by localized, moderate pain and the associated swelling and irritation of the throat and mouth lining, which may include irritation from oral mucosal lesions. The lozenge is intended for use in situations where these types of localized discomfort occur. This supports easing the impact of the inflammation, which supports patients coping more steadily with difficult episodes.


The formulation is applicable in contexts where increased patient discomfort is caused by difficulty and discomfort upon swallowing (dysphagia). This preparation assists with addressing symptom patterns characteristic of irritation and is often used when symptoms escalate temporarily and short-term symptomatic assistance is needed.

Quick Fact: Supportive Benefit

  • Symptoms: Helps address symptom clusters that may become intense or disruptive.
  • Conditions: Relevant in conditions characterized by periods of heightened symptoms.
  • Benefit: Provides supportive relief when symptoms interfere with routine activities.

Symptom Management in Irritative States

The preparation is applied in contexts where additional support for symptom management is needed, particularly in irritative states. It offers symptomatic relief that helps address groups of symptoms that may appear suddenly and create noticeable interference with daily functioning. The formulation provides supportive relief when symptoms interfere with routine activities and supports short-term symptomatic assistance when symptoms become temporarily overwhelming.

Eligibility and Restrictions for Use

Official Eligibility Rules for Use

Official regulatory documents define specific populations who are eligible for Difflam Anti-Inflammatory Lozenges, as well as groups for whom use is contraindicated or restricted. This information is based on the active ingredients, Benzydamine and Cetylpyridinium Chloride.


Eligibility Status by Population

Population Group Regulatory Status
Adults and Adolescents (12+ years) Eligible for use under standard labeled conditions.
Children 6–12 years Eligible, but must use under adult supervision.
Children under 6 years Contraindicated (must not use).
Pregnancy and Lactation Not Recommended or Should Not be Used due to limited data.

Mandatory Restrictions and Caution

Use of this medicine is contraindicated for patients with a known hypersensitivity to the active substances or any of the lozenge's excipients. Furthermore, use is not advisable in patients with a known sensitivity to aspirin or other Non-Steroidal Anti-inflammatory Drugs (NSAIDs).

Caution must be exercised in patients with a history of bronchial asthma, as use may lead to bronchospasm. Consideration of potential systemic effects is required for patients with severe hepatic or renal impairment.

What should I know about interactions with other medicines?

Systemic and Metabolic Interactions

Regulatory documentation confirms that formal systemic pharmacokinetic interactions are not documented for this fixed-dose combination product. Due to the low systemic absorption of Benzydamine and the poor systemic absorption of Cetylpyridinium Chloride, there is no official documentation of interactions involving the cytochrome P450 (CYP) enzyme system or drug transporters that would alter the clearance or exposure of co-administered systemic medicines. No specific medicinal products are explicitly classified as contraindicated due to a systemic interaction risk with this lozenge in official labeling.

Local Pharmacodynamic Restrictions

The documented interactions are local and relate to the efficacy of the Cetylpyridinium Chloride antiseptic component. Co-administration with anionic compounds, such as those typically found in toothpastes, is officially restricted because these substances are documented to reduce the antimicrobial effectiveness of the lozenge. Regulatory text, therefore, recommends against using the lozenge immediately before or immediately after cleaning teeth. The lozenge should also not be used simultaneously with other antiseptic agents due to potential additive local effects.

Drug–Food Interactions

A specific drug–food interaction is documented: the lozenges should not be taken together with milk. Official information confirms that milk reduces the antimicrobial efficacy of the Cetylpyridinium Chloride component. No other formal interaction patterns with alcohol or herbal products are explicitly documented in the official regulatory labeling.

Mechanism of Action

How Difflam Anti-Inflammatory Lozenges Works

The lozenge utilizes a dual-action mechanism through Benzydamine HCl (anti-inflammatory/analgesic) and Cetylpyridinium Chloride (CPC) (antiseptic). This combination modulates host response pathways and disrupts surface microbial cell integrity.


Modulation of Upstream Inflammatory Signaling

Benzydamine's primary anti-inflammatory mechanism involves the inhibition of pro-inflammatory cytokine synthesis, notably TNF-alpha and IL-1beta, acting upstream in the inflammatory cascade. This action modifies cellular responses, such as neutrophil degranulation and leukocyte migration, which leads to a physiological attenuation of localized tissue oedema and hyperaemia.


Peripheral Nociceptor Blockade and Membrane Stabilization

Benzydamine functions as a local analgesic by interacting directly with the cationic channels of peripheral nerve endings, effectively stabilizing the neuronal membranes. This direct modulation of membrane excitability creates a blockade of pain impulse generation and transmission along the peripheral nerves at the site of contact. This results in a localized reduction in the excitability of nociceptive pathways (local anaesthetic effect).


Disruption of Microbial Cell Integrity

The second component, Cetylpyridinium Chloride, contributes a complementary mechanism by acting as a cationic surfactant. It targets the negatively charged microbial cell membranes, causing physical disruption and a loss of cellular contents. This process leads to the disruption of microbial cell viability on the oromucosal surface, which restricts the constant biological stimulus on local host tissue.

Dosage and Administration Information

Instruction Map: How to use Difflam Anti-Inflammatory Lozenges — Official Administration Guidelines

Administration Scope

Route of administration: The product is intended for oromucosal administration, meaning the lozenge is used for localized topical application to the lining of the mouth and throat.

Dosing schedule: The standard single dose is one lozenge. Dosage frequency is symptom-dependent, typically administered every 3 to 6 hours. Frequency may be increased to every 1 to 2 hours in some contexts. The maximum daily dose is restricted either to 3 to 4 lozenges or up to a maximum of 12 lozenges per 24-hour period.

Timing in relation to meals (if applicable): For proper localized effect, instructions state that the lozenge should not be taken immediately before or after cleaning teeth and recommend avoiding eating or drinking for at least one hour following administration.

Age-group administration rules:

  • Adolescents (over 12 years): The dosage regimen is the same as the standard adult dose.
  • Children (6 to 12 years): Use is subject to adult supervision, and a restricted maximum daily dose (e.g., 3 lozenges a day) is specified.
  • Children (under 6 years): The product must not be given.

Special procedural conditions: The lozenge must be slowly dissolved in the mouth to facilitate the localized release of the agents; it must not be chewed or swallowed whole.


Instruction Classifications (High-Level)

Administration method type: Topical/Local (via oromucosal route)

Frequency pattern: As-needed basis (PRN), subject to a maximum daily dose and minimum interval between administrations.

Course duration / cycle information: Uninterrupted treatment should not exceed 7 days. If symptoms do not improve after 3 days, use should cease in accordance with standard product labeling.


Connection to the Overall Use Protocol

The administration guidelines establish a controlled protocol that defines the oromucosal delivery and the boundaries for both the single unit dose and the total daily exposure. These constraints, which include limits on treatment duration and age-specific rules, define the standardized, short-term usage pattern.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Difflam Anti-Inflammatory Lozenges

Evidence for use in Sore Throat

Research has explored the use of this product in individuals facing conditions characterized by fluctuating or episodic manifestations such as a sore throat. Studies primarily involve short-term, controlled trials that monitored outcomes related to physical discomfort over defined time intervals, usually a few hours. These studies examined changes in patient-reported outcomes describing perceived discomfort in typically adult populations with acute, non-severe throat pain.

The research describes short-term patterns observed where a difference in the measurement of throat discomfort was observed in the study group. These findings indicate that research highlights changes measured during the study period, contributing to the understanding of short-term symptom patterns. However, these data show patterns related to only acute, temporary observations, and the full extent of these patterns may vary between individuals.

Evidence for use in Pharyngitis and Tonsillitis

Clinical research was evaluated in individuals presenting with conditions involving periods of heightened symptoms such as acute pharyngitis and tonsillitis. Studies monitored patient-reported measures of pain and difficulty swallowing, which are outcomes reflecting daily functioning or activity level.

The research describes the short-term findings of these trials. Findings were mixed regarding the patterns of change observed, but overall, research describes patterns observed in some individuals related to outcomes capturing phases of heightened symptom activity. Data for certain groups remain insufficient, particularly concerning the range of severity of these conditions that was evaluated in the studies.

What the Research Does Not Yet Fully Characterize

The overall evidence landscape is characterized by several limitations. Long-term effects are not fully established, and follow-up durations were limited across the primary studies. This means that data for extended use over several weeks or months is not available. Comparative evidence is lacking to fully understand how the observed patterns relate to other non-prescription options. Research provides context but not individual predictions.

Key Studies & References

  1. Summary of Product Characteristics (SPC) - Benzydamine lozenges (Tantum Verde)
  2. Benzydamine hydrochloride on postoperative sore throat: A meta-analysis of randomized controlled trials
  3. The present and the future of benzydamine: expert opinion paper
  4. Double-blind study of benzydamine hydrochloride, a new treatment for sore throat
  5. Public Assessment Report Scientific discussion Zotrina 3 mg lozenges honey-orange (Benzydamine hydrochloride)

Frequently Asked Questions (FAQ)

Common questions about Difflam Anti-Inflammatory Lozenges (FAQ)


Q: How quickly should I expect Difflam lozenges to start working?

Studies on the lozenge combination indicate that the onset of pain relief, specifically the reduction of throat soreness, has been observed to begin within about 15 minutes of administration. This localized action of the active ingredients is intended to target the site of discomfort directly.


Q: How long does the pain relief from one Difflam lozenge last?

Clinical studies have shown that the pain-relieving effects of a single lozenge typically extend for up to 3 hours. This duration of action aligns with the guidelines for when a patient may consider taking the next lozenge, as directed by the product label.


Q: Can I take Difflam lozenges while taking a standard paracetamol tablet?

Regulatory information indicates that formal systemic pharmacokinetic interactions are not documented for these lozenges. This is due to the low amount of active ingredient that is absorbed into the bloodstream. Consulting a healthcare provider is recommended when combining any medications.


Q: Does Difflam interact with alcohol consumption?

The official product information does not list any known drug interactions between the lozenges and consumption of alcohol. As with any acute throat condition, general guidance suggests avoiding irritants like alcohol.


Q: Do Difflam lozenges contain any sugar or artificial sweeteners?

Many Difflam lozenge products are formulated to be sugar-free. These products often use excipients like Isomalt and Sucralose (or other saccharin derivatives) as sweeteners and bulking agents. The specific list of excipients, including sweeteners, can be found by reviewing the product packaging.


Q: Why does my throat still hurt after using a Difflam lozenge for a few days?

If your sore throat or related symptoms do not show signs of improvement after 3 days of using the lozenges, the regulatory label advises seeking advice from a doctor or pharmacist. The regulatory label indicates that continued use beyond this threshold for unresolved symptoms should be managed under the advice of a healthcare professional.


Q: Can Difflam lozenges cause stomach upset or nausea?

Official safety documentation notes that the most frequently reported adverse reactions are localized effects in the mouth, such as stinging, burning, or numbness. Generalized stomach upset or nausea are not among the commonly listed side effects.


Q: Can elderly patients use Difflam without any special precautions?

Official regulatory documents indicate that the recommended dosage for elderly patients is the same as the standard adult dose. There are no specific age-related precautions listed for the elderly in the dosing instructions. However, regulatory caution is applied to all patients with severe liver or kidney impairment, regardless of age.


Q: Can people with diabetes safely use the lozenges?

Yes, many Difflam lozenge products are specifically formulated and labeled as 'Sugar Free,' making them generally suitable for use by individuals with diabetes. It is recommended to confirm the 'Sugar Free' designation on your specific product package.


Q: Can Difflam Anti-Inflammatory Lozenges help with tonsillitis pain?

Yes, the product is officially indicated for the temporary relief of painful conditions of the oral cavity and throat, which includes the pain associated with tonsillitis. The product’s anti-inflammatory and analgesic actions are intended to help relieve symptoms of swelling and localized pain.


Q: Is it normal to feel numbness in my mouth after using a Difflam lozenge?

Yes, it is listed as a common local side effect. Numbness in the mouth or throat may occur after using the lozenge due to the local analgesic component of the medicine.


Q: Are there any long-term side effects from using Difflam lozenges regularly?

The product is designed for short-term, acute symptom relief. Official guidelines specify a limited duration for continuous, uninterrupted use. Regulatory warnings state that using the product for long periods of time may carry an increased risk of local sensitivity (sensitisation).


Q: Do Difflam lozenges lose effectiveness if they expire?

Yes, the official product labeling strictly advises against using the lozenges after the expiration date printed on the package. This instruction is critical to ensure the product maintains its stated stability and integrity.


Q: Can Difflam lozenges be used for mouth ulcers or just the throat?

The product is indicated for the temporary relief of painful conditions that affect the entire oral cavity, including mouth ulcers (aphthous ulcers), sore throat, and inflamed gums. The indication is not limited to throat symptoms, but covers painful conditions throughout the oral cavity.


Q: Does Difflam interact with herbal supplements like Echinacea?

Official information advises that there may not be sufficient safety data available regarding the use of complementary medicines, herbal remedies, and supplements with the active ingredients. It is advisable to inform a healthcare provider about any supplements being taken.


Q: Is there any research on Difflam's effectiveness for pain after dental work?

Yes, the product is indicated for the relief of local pain and discomfort that occurs following certain dental procedures or surgery in the mouth or throat area. This use is cited in the official product information.


Q: Is there a link between Difflam use and experiencing a dry mouth?

Yes, a feeling of dryness in the throat or an increase in thirst has been listed as a documented adverse reaction in some product information. If this or any other side effect becomes severe or concerning, patients are advised to seek guidance from a healthcare professional.


Q: Do Difflam lozenges interact with common cold and flu medicines?

The active ingredients have low systemic absorption, meaning they are unlikely to cause formal systemic interactions with most common cold and flu medicines. As with all medications, official information recommends informing a healthcare provider of all medicines being taken to prevent any unknown interactions.


Q: What are the possible signs of an allergic reaction to Difflam?

Rare and very rare allergic reactions include symptoms such as hives, rash, severe dizziness, swelling (especially of the face, tongue, or throat), or trouble breathing. If these or similar signs of an allergic reaction are experienced, immediate medical assistance should be sought.


Q: Is the sensation of tingling normal when the lozenge is dissolving?

Official adverse reaction profiles list a 'stinging feeling' or 'burning of the oral mucosa' as documented local effects that may occur. This sensation is typically temporary and related to the medication making contact with the irritated tissue.


Q: Does Difflam affect the ability to taste food or drinks?

Temporary changes in sensation have been reported. Some documentation lists a local adverse reaction of feeling 'stale' or 'dry' in the mouth, which could temporarily affect taste perception while the lozenge is active.


Q: Are there any known drug interactions with common anti-depressants?

Due to the low systemic absorption of the active ingredients, formal systemic drug interactions with most medicines, including common anti-depressants, are not documented. It is recommended to inform your healthcare provider about all prescription medications being taken.


Q: Are there studies comparing the effectiveness of different lozenge ingredients?

Research overviews note that while studies have been conducted on this specific lozenge combination, comparative evidence is currently lacking. Full comparisons of its observed patterns versus other non-prescription options are generally unavailable in the literature.


Q: Is the effect of Difflam purely local, or is there systemic absorption?

The product is designed to provide relief via a localized effect, acting where the lozenge dissolves. While the effect is localized, the active ingredients do undergo minimal systemic absorption into the body.


Q: Why do some Difflam lozenges contain Benzydamine and others Povidone-iodine?

The Difflam brand includes a range of products designed for different purposes and using different active ingredients. Other Difflam formulations, such as gargles, may contain different active ingredients, like Povidone-iodine, to offer a variety of antiseptic and anti-inflammatory options under the same brand name.

How should Difflam Anti-Inflammatory Lozenges be stored and disposed of?

Difflam lozenges must be stored strictly according to the conditions listed on the official product labeling to maintain stability and integrity.

Category Regulatory Requirement
Maximum Temperature Store at a temperature not exceeding 30°C.
Protection Conditions Store in the original package to protect from light and moisture.
Child Safety Keep this medicine out of the sight and reach of children.
Stability Restriction Do not use the lozenges after the expiry date.

Disposal instructions require that any unused or expired lozenges must not be thrown away via wastewater or household waste to protect the environment. The product must be disposed of in accordance with local requirements for pharmaceutical waste, which typically involves collection points or a pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Difflam Anti-Inflammatory Lozenges found in:

A-Z Index: